POTTERY BARN ANNOUNCES GLOBAL COLLABORATION WITH DEEPIKA PADUKONE

4 years ago

Internationally Acclaimed Actor and Global Style Icon Will Collaborate with Pottery Barn as Part of Brand’s International Expansion SAN FRANCISCO--(BUSINESS…

Québec Nickel Corp. Announces Closing of the First Tranche of Its Previously Announced Private Placement

4 years ago

VANCOUVER, British Columbia--(BUSINESS WIRE)--Québec Nickel Corp. (CSE: QNI) (“Québec Nickel Corp.” or the “Company”) is pleased to announce that it…

Québec Nickel Corp. Announces Closing of the First Tranche of Its Previously Announced Private Placement

4 years ago

VANCOUVER, British Columbia--(BUSINESS WIRE)--Québec Nickel Corp. (CSE: QNI) (“Québec Nickel Corp.” or the “Company”) is pleased to announce that it…

ONE Championship Welcomes Stage Front VIP as Global VIP Experience Partner

4 years ago

Experiences for ONE’s U.S. Debut in 2023 to be Announced in Near Future SINGAPORE--(BUSINESS WIRE)--ONE Championship™ (ONE), the world’s largest…

ONE Championship Welcomes Stage Front VIP as Global VIP Experience Partner

4 years ago

Experiences for ONE’s U.S. Debut in 2023 to be Announced in Near Future SINGAPORE--(BUSINESS WIRE)--ONE Championship™ (ONE), the world’s largest…

Looking for a holiday gift? Choose Rokid Air and feel the thrill of carrying a big screen in your pocket

4 years ago

HANGZHOU, China--(BUSINESS WIRE)--The holiday season is back! How do you get your favorite entertainment whenever, wherever? During the holidays, augmented…

Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in Patients with Metastatic Triple Negative Breast Cancer in Two Early Trials

4 years ago

Daiichi Sankyo and AstraZeneca’s TROP2 directed ADC showed an encouraging objective response rate of 32% and a manageable safety profile…

Datopotamab Deruxtecan Showed Promising Responses as Monotherapy and in Combination with Durvalumab in Patients with Metastatic Triple Negative Breast Cancer in Two Early Trials

4 years ago

Daiichi Sankyo and AstraZeneca’s TROP2 directed ADC showed an encouraging objective response rate of 32% and a manageable safety profile…

Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases

4 years ago

? Company to Feature 15 Company-Sponsored and Nine Collaborative Abstracts in Oncology and Hematology ? Oral Presentations Include Updated Results…

Azura Ophthalmics Presents Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction at Ophthalmology Innovation Summit XII

4 years ago

TEL AVIV, Israel & MELBOURNE, Australia--(BUSINESS WIRE)--Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic…